¿´Æ¬ÊÓƵ

Object moved to here.

¿´Æ¬ÊÓƵ :: Pilot & Feasibility Program Application

¿´Æ¬ÊÓƵ


Arsenic Exposure, Endothelial Function and Platelet Activity in Type 2 Diabetes
Summary Data Summary
Applicant Newman, Jonathan
E-Mail Address Jonathan.Newman@nyumc.org
Project Title Arsenic Exposure, Endothelial Function and Platelet Activity in Type 2 Diabetes
CBU ID 14GHSU1423
External SubContract ID 25732-60
Diabetic Complication Cardiovascular
Funding Program Group Pilot & Feasibility [PF2014]
Abstract Despite optimal medical therapy to reduce cardiovascular disease (CVD) risk,
patients with type 2 diabetes (T2D) have a significantly greater risk of CVD
than patients without T2D. Data from the prospective NIH/NHLBI Strong Heart
Study suggested low to moderate inorganic arsenic exposure may be a novel risk
factor for CVD, especially for patients with T2D. In the United States, exposure
to inorganic arsenic at low to moderate levels is common, with millions of
people exposed annually in the U.S. through food and drinking water. However,
the mechanisms by which low to moderate arsenic exposure may increase CVD risk
in patients with T2D have not been characterized. Therefore, our aims are to:
(1) investigate whether increasing concentrations of glucose modify the effects
of low to moderate concentrations of sodium arsenite on markers of human aortic
and coronary endothelial cell dysfunction; and (2) investigate whether
increasing concentrations of glucose modify the effects of low to moderate
concentrations of sodium arsenite on platelet function and aggregability. This
proposal will provide novel insights into the associations among low to moderate
arsenic exposure, T2D, markers of endothelial dysfunction and platelet activity
for the risk of CVD. These studies would be the first to examine in two model
systems the effect of environmental modifiers such as arsenic exposure on the
risk of CVD in T2D, and could be used to explore the risk of other environmental
exposures as contributors to the excess risk of CVD in patients with T2D.
Application PDF Application Research Plan
Status Contract Executed
Key Personnel
Salary Total Costs 37269
Supply Total Costs 18500
Equipment Total Costs 1250
Travel/Other Total Costs 1500
Direct Costs 58519
Indirect Costs Proposed 40671
Total Costs Proposed 99190
Total Costs Approved 99190
Start Date 10/1/2014
End Date 9/30/2015
IFO Name Carna, Anthony
IFO E-Mail Address grants.office@med.nyu.edu
IACUC/IRB No. 999999
IACUC/IRB Institution New York University School of Medicine
Entity ID No. 1135562309A1
Report Request Date 10/30/2015
T1D NO
TypeCount
Invoices 3
Progress Reports 1
Data Submission


Invoices
UrlCBU IDExternal IDInstitutionDateDirectIndirectInvoiceBalancePDF
  View  14GHSU142325732-60New York University School of Medicine7/16/2015$38,770.98-$38,770.98-View PDF
  View  14GHSU142325732-60New York University School of Medicine4/14/2015$13,650.31-$13,650.31-View PDF
  View  14GHSU142325732-60New York University School of Medicine12/14/2015$46,768.71-$46,768.71-View PDF
Click here to cancel and return to funding program application

*Author:
*SubContract:
*Select File:

Click browse and select the file to upload.
(Please upload ONLY TXT, Image Files (not histolgy), PDF, XLS, XLSX, DOC, or DOCX files.)